Outpatient EUS gastrocholecystostomy for symptomatic gallbladder distension

Gianfranco Donatelli, MD,1 Fabrizio Cereatti, MD,2 Jocelyn Privat, MD,3 David Fuks, MD, PhD,4 Jean-Loup Dumont, MD5

Biliary stent placement has become widely accepted as a standard procedure for palliation of jaundice in patients with unresectable malignant biliary strictures. The rate of cholecystitis after ERCP with or without self-expandable metal stent (SEMS) deployment ranges from 5% to 11%.1,2 The use of fully covered SEMSs (FCSEMSs) theoretically may increase the risk of cholecystitis because of obstruction of the cystic orifice; however, contrasting data were reported.3

Meanwhile, tumoral involvement of the cystic orifice is considered to be an important risk factor for cholecystitis after SEMS placement.4 Acute cholecystitis or symptomatic gallbladder hydrops related to cystic duct malignant obstruction requires urgent gallbladder drainage because affected patients are often unfit for surgery.

We report the case of an 80-year-old woman undergoing ERCP for palliation of obstructive jaundice due to unresectable pancreatic cancer.

After common bile duct cannulation and cholangiography, a 10- × 60-mm FCSEMS (Wallflex; Boston Scientific, Natick, Mass, USA) was inserted to overcome a severe neoplastic stricture on the middle part of the common bile duct. The stricture involved the cystic duct orifice (Fig. 1). Pneumobilia after FCSEMS deployment, confirming stricture resolution, was seen on the cholangiogram (Fig. 2). The postoperative course was uneventful, and...
the patient was discharged in good clinical condition on postprocedural day 1.

After 1 week, she was seen again because of severe abdominal pain in the right hypochondrium and a palpable right upper-quadrant mass. A laboratory chemistry test highlighted leukocytosis (22,000 \( \times \) 10\(^9\)/L) and increased level of C-reactive protein up to 390 U/L. A CT scan showed a marked distension of the gallbladder without wall thickness and ascites (Fig. 3). Percutaneous cholecystostomy was not performed in the primary hospital because of ascites. Therefore, she was transferred to our tertiary center, and emergency EUS-guided gastrocholecystostomy was performed with the patient under general anesthesia and a Hot Axios (15-mm \( \times \) 10-mm) (Boston Scientific) was deployed (Fig. 4). Hot Axios deployment induced immediate symptom resolution (Video 1, available online at www.VideoGIE.org).

Oral diet was restarted after 3 hours, and the patient was discharged on the day of the procedure. Early discharge was feasible because these criteria had been fulfilled: the patient’s excellent clinical condition, home distance from hospital within 100 km, and presence of an in-home, trained caregiver. No adverse events occurred after a follow-up time of 2 months. The patient, although experiencing wasting syndrome, eats normally and no longer needs pain medication.

EUS-guided drainage of the gallbladder is becoming the criterion standard treatment for acute cholecystitis in high-risk patients. Several studies showed a higher technical and clinical success rate of the EUS approach compared with the percutaneous or transcytotic approach. Moreover, EUS drainage seems to have significantly fewer long-term adverse events and a lower rate of reintervention compared with the percutaneous approach.

Here we have reported a case of EUS-guided gallbladder drainage with a lumen-apposing metal stent for acute symptomatic gallbladder distension in an outpatient setting. This procedure could be considered feasible, safe, and effective for the management of symptomatic gallbladder pathologic conditions, even in an outpatient setting, as long as no signs of general sepsis are present and an intact gallbladder wall is confirmed at preprocedural imaging.

In a similar scenario, when palliative treatments are needed in end-stage patients, the ability to guarantee a 1-day procedure may significantly improve the patient’s quality of life.

**DISCLOSURE**

All authors disclosed no financial relationships relevant to this publication.

Abbreviations: FCSEMS, fully covered SEMS; SEMS, self-expandable metal stent.

**REFERENCES**

1. Suk KT, Kim HS, Kim JW, et al. Risk factors for cholecystitis after metal stent placement in malignant biliary obstruction. Gastrointest Endosc 2006;64:522-9.
2. Coté GA, Kumar N, Ansstas M, et al. Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc 2010;72:748-54.
3. Kullman E, Frozanpor F, Soderlund C, et al. Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study. Gastrointest Endosc 2010;72:915-23.
4. Shimizu S, Naitoh I, Nakazawa T, et al. Predictive factors for pancreatitis and cholecystitis in endoscopic covered metal stenting for distal malignant biliary obstruction. J Gastroenterol Hepatol 2013;28:68-72.
5. Law R, Perez-Miranda M. Is it time to stop using percutaneous transhepatic biliary drainage? Endoscopy 2017;49:521-3.
6. Siddiqui A, Kunda R, Tyberg A, et al. Three-way comparative study of endoscopic ultrasound-guided transmural gallbladder drainage using lumen-apposing metal stents versus endoscopic transpapillary drainage versus percutaneous cholecystostomy for gallbladder drainage in high-risk surgical patients with acute cholecystitis: clinical outcomes and success in an international, multicenter study. Surg Endosc. Epub 2018 Sep 24.
7. Oh D, Song TJ, Cho DH, et al. EUS-guided cholecystostomy versus endoscopic transpapillary cholecystostomy for acute cholecystitis in high-risk surgical patients. Gastrointest Endosc 2018;98:289-98.
8. Choi JH, Kim HW, Lee J, et al. Percutaneous transhepatic versus EUS-guided gallbladder drainage for malignant cystic duct obstruction. Gastrointest Endosc 2017;85:357-64.

Unité d’Endoscopie Interventionnelle, Hôpital Privé des Peupliers, Ramsay Générale de Santé, Paris, France (1); Gastroenterologie ed Endoscopia Digestiva ASST Cremona, Cremona, Italy (2); Service d’Hépato-gastro-entérologie, CH Jacques Lacarin, Vichy, France (3); Department of Digestive Surgery, Institut Mutualiste Montsouris, Paris, France (4); Unité d’Endoscopie Interventionnelle, Hôpital Privé des Peupliers, Ramsay Générale de Santé, Paris, France (5).

Copyright © 2019 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

https://doi.org/10.1016/j.vgie.2019.01.001